- Who Were the Biggest Winners And Losers This Year?
- GE, Comcast Complete Deal Over NBC Universal: Source
- US May Raise Rates Before Jobs Recover: Fed's Plosser
- Cramer: Watch Tech Stocks on Wednesday – Here’s Why
- Stocks Likely Don't Need Santa to Keep Rally Going
- Larry Kudlow's Open Letter to Tiger Woods
- Super Fantasy Christmas Gifts of 2009
- AIG Slashes US Debt Under Deal With New York Fed
- Seamstress Fined $5.7 Million for Insider Trading
- 8 Stocks to Gain on Obama's Afghan Plan: Analysts
- BofA On Proposed Changes In The Housing Bailout Program
- The Future of The Media Landscape
- November Auto Sales Muddle Along
- Busch: What Obama Won't Say Tonight
- Stick with Equities—Avoid Emerging Markets: Laszlo Birinyi
- Pfizer Chomps On A Carrot
- Predictions 2010: Technology
- Predictions 2010: Consumers
Text Size 
Amgen reported quarterly results that outpaced what Wall Street was expecting, and the company boosted its outlook for its full-year profit. But the company's shares declined in extended trading.
The pharmaceutical company earned $1.49 a share in its third quarter excluding one-time items, compared with $1.23 a share in the same period last year.
Sales for the most recent quarter reached $3.81 billion, down from $3.875 billion this time last year.
Analysts who follow Amgen expected the company to turn in a profit of $1.27 a share on sales of $3.793 billion, according to a consensus estimate rom Thomson Reuters.
 |
Worldwide sales of Amgen's once top-selling anemia drug Aranesp, which have been badly hurt by safety concerns and reimbursement restrictions, continued their steep decline. Aranesp sales fell 19 percent to $685 million, well off analyst estimates of $698 million and below the previous quarter's $693 million.
Amgen also said that the U.S. Food and Drug Administration wants more information about Prolia, a proposed bone-loss treatment from the company.
The news on Prolia and Aranesp appeared to hurt Amgen shares, which declined more than 5 percent in extended trading Wednesday. Get after-hour quotes for Amgen here.
During the Nasdaq's regular session, the stock [AMGN
Loading...
()
] rose about 2 percent to $59.40.
Amgen stock rose 13.7 percent to end the quarter at $60.23. The shares managed to avoid the volatility seen in other health care sectors as the debate over health care reform continues.
- Reuters and AP contributed to this report.
- Will the Fed raise rates? Will the dollar continue its slide? CNBC experts weigh in on the year ahead.
- Goldman Sachs has forbidden employees from gathering in private holiday parties of 12 or more.
- Do you have what it takes to run your own business? Ask yourself these questions.
- Heavily armed pirates in Somalia have set up a sort of stock exhange to fund their hijackings.
- Since its launch in 1998, Google has become a primary force on the Internet. How much do you know about the company?
- A famed author has written all his work on an old typewriter that is now up for auction. The NYT reports.
Data is a real-time snapshot *Data is delayed at least 15 minutes